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Introduction 1 
Oxaliplatin, a third-generation platinum chemotherapeutic agent, is associated with acute 2 
dose-limiting neurotoxicity, which manifests as cooling-induced peripheral dysaesthesias and 3 
paraesthesias including cold allodynia [6; 12]. Acute oxaliplatin-induced cold allodynia is 4 
characterized by a rapid onset, with symptoms occurring during or shortly after infusion, and 5 
typically resolves within several days of treatment [5]. Many currently used animal models of 6 
oxaliplatin-induced neuropathy poorly reflect these characteristics, and often require multiple 7 
injections of oxaliplatin to elicit pain behaviours which develop slowly and are of prolonged 8 
duration [30; 40; 56]. Mechanistic studies in these animal models have attributed expressional 9 
changes and altered function of ion channels expressed on unmyelinated C-fiber nociceptors 10 
to the development of cold allodynia, such as the transient receptor potential (TRP) channels 11 
TRPM8, TRPA1 and the two-pore domain potassium (K
+
) channels TREK1 and TRAAK [16; 12 
21; 35; 60]. However, these findings are inconsistent with the clinical time course of acute 13 
oxaliplatin-induced cold allodynia and the predominant effects of oxaliplatin on myelinated 14 
A-fibers [2; 6; 27; 46; 47]. Thus, the pathophysiological mechanisms underlying acute 15 
oxaliplatin-induced cold allodynia remain unclear. While oxaliplatin-induced allodynia has 16 
been described as an axonal channelopathy resulting from modulation of neuronal Nav 17 
channels [36], the contributions of the nine described isoforms (Nav1.1 – Nav1.9) have not 18 
been systematically assessed. 19 
Dorsal root ganglion (DRG) neurons express several Nav isoforms, including the tetrodotoxin 20 
(TTX) resistant isoforms Nav1.8 and Nav1.9, as well as the TTX-sensitive isoforms Nav1.1, 21 
Nav1.2, Nav1.3, Nav1.6 and Nav1.7 [41]. The TTX-resistant Nav isoform Nav1.8 in particular 22 
has been found to be crucial for pain evoked by noxious cooling [61], while Navl.9 has been 23 
suggested to contribute to the pathogenesis of neuropathic pain [29]. In addition, Nav1.7 is 24 
known to be crucial in pain pathways, as loss-of-function mutations in humans cause 25 
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congenital insensitivity to pain [14], while gain-of-function mutations are associated with 1 
painful conditions such as erythromelalgia and paroxysmal extreme pain disorder [19]. In 2 
contrast, the functional roles of Nav1.1 and Nav1.6 in peripheral sensory neurons are less clear, 3 
and no evidence for involvement of these Nav isoforms in pain phenotypes has been reported 4 
to date, as both homozygous Scn1a
–/–
 and Scn8a
–/–
 mice develop motor deficits and die 5 
around postnatal day 15 to 20, preventing assessment of behavioural effects in mature animals 6 
[9; 57]. 7 
We established an animal model of oxaliplatin that more closely mimics acute chemotherapy-8 
induced peripheral neuropathy. We found that intraplantar oxaliplatin rapidly induced a long-9 
lasting cold allodynia that was mediated entirely through TTX-sensitive Nav isoform-10 
dependent pathways. Surprisingly, Nav1.6 was implicated as the key Nav isoform involved, 11 
whereas thermosensitive TRP channels were not found to be involved. Consistent with reports 12 
of a crucial role for delayed-rectifier potassium channels in excitability in response to cold 13 
[53], intraplantar administration of the K
+
 channel blocker 4-aminopyridine (4-AP) mimicked 14 
oxaliplatin-induced cold allodynia and was inhibited by Navl.6 blockers or potentiated by 15 
Nav1.6 activators, supporting a crucial role for Navl.6 in chemically-mediated cold pain 16 
pathways. 17 
 18 
Methods 19 
Chemicals 20 
Oxaliplatin and Dichloro(1,2-diaminocyclohexane)platinum(II) (Pt(DACH)Cl2) were 21 
obtained from Sigma Aldrich (Castle Hill, New South Wales, Australia) and dissolved in 5% 22 
glucose/H2O to a stock solution of 1 mg/mL to avoid spontaneous hydrolysis arising from the 23 
presence of Cl
-
 in physiological solutions. µ-Conotoxins GIIIA and TIIIA were a kind gift 24 
from Professor Paul F. Alewood, The University of Queensland, Australia. Cn2 was isolated 25 
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from the venom of the scorpion Centruroides noxius as previously described [44; 58]. M8-B 1 
(N-(2-aminoethyl)-N-(4-(benzyloxy)-3-methoxybenzyl)thiophene-2-carboxamide 2 
hydrochloride), a selective and potent antagonist of TRPM8) , was synthesized and kindly 3 
provided by Amgen, Inc. [4]. The TRPM8 antagonist AMTB (N-(3-Aminopropy1)-2-[(3-4 
methylphenyl)methoxy]-N-(2-thienylmethyl)benzamide hydrochloride) and tetrodotoxin were 5 
from Tocris Bioscience (Bristol, United Kingdom). ProTxII was from Peptides International 6 
(Louisville, KY, USA). Peptides were routinely diluted in 0.1–0.3% albumin in phosphate-7 
buffered saline to avoid adsorption to plastic surfaces. All other drugs and pharmacological 8 
modulators were diluted in phosphate-buffered saline. All other reagents were from Sigma 9 
Aldrich unless otherwise stated. 10 
 11 
Animals 12 
Ethical approval for in vivo experiments in animals was obtained from the local institutional 13 
animal ethics committee. Experiments involving animals were conducted in accordance with 14 
the Animal Care and Protection Act Qld (2002), the Australian Code of Practice for the Care 15 
and Use of Animals for Scientific Purposes, 7th edition (2004) and the International 16 
Association for the Study of Pain Guidelines for the Use of Animals in Research. 17 
 18 
For behavioural assessment of oxaliplatin-induced neuropathy, we used adult male C57BL/6J 19 
mice, age 5–12 weeks. Age-matched controls were used for studies involving knockout 20 
animals, and all mouse strains were back-crossed for a minimum of 5 (5–9) generations on 21 
C57BL/6 background. Knockout animals were kindly provided by the following researchers: 22 
TRPA1
–/–
 mice (D. Corey, Harvard Medical School, Boston, MA, USA), TRPM8
–/–
 mice (A. 23 
Patapoutian, The Scripps Research Institute, La Jolla, CA, USA), global Navl.8
–/–
, Navl.9
–/–
, 24 
and Navl.3
–/–
 mice (J. Wood, University College London, London, UK).   25 
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 1 
Induction of oxaliplatin-induced neuropathy and behavioural assessment 2 
To characterize nociceptive effects in wild-type C57BL/6J and age-matched TRPA1
–/–
, 3 
TRPM8
–/–
, Navl.8
–/–
, Navl.9
–/–
 and Nav1.3
–/– 
mice, a single dose of oxaliplatin, oxalate, 4 
Pt(DACH)Cl2, 4-AP or Cn2 was administered by shallow subcutaneous injection to the left 5 
hind paw in a volume of 40 µl (intraplantar injection, i.pl.) under light isoflurane anaesthesia. 6 
Quantification of spontaneous pain, cold and heat allodynia as well as mechanical allodynia 7 
was performed by a blinded observer unaware of the genotype and/or treatments received. 8 
Spontaneous nocifensive behaviour was quantified by counting the number of paw lifts, licks, 9 
shakes and flinches at room temperature (22–25°C) on a soft padded surface over a period of 10 
5 min. Thermal allodynia was assessed by quantification of nocifensive behaviours over a 5 11 
min period on a temperature-controlled Peltier plate (Hot/Cold Plate, Ugo Basile, Comerio, 12 
Italy). Mechanical allodynia was assessed by determining the paw withdrawal threshold to 13 
mechanical stimulation using an electronic von Frey apparatus (MouseMet Electronic von 14 
Frey, TopCat Metrology, Little Downham, United Kingdom). Briefly, mice were habituated 15 
in individual mouse runs for at least 10 min, and the paw withdrawal threshold was 16 
determined from the ipsilateral and controlateral paws in three separate trials, at least 5 min 17 
apart. The pressure applied through a soft-tipped probe was increased slowly over a pre-18 
determined force rise rate (1 g/s). The force that elicited paw withdrawal was determined 19 
using the MouseMet Software and designated as the paw withdrawal threshold.   20 
Where intraplantar injection elicited nocifensive behaviour at room temperature (Cn2, 21 
BAPTA, oxalate, 4-AP), thermal and mechanical allodynia was assessed after cessation of 22 
spontaneous pain (15 min to 1 h). To assess the effects of pharmacological modulators on the 23 
development of oxaliplatin-induced cold allodynia, compounds were administered by 24 
intraplantar injection of appropriately concentrated solutions (HC030031, 100 µM; AMTB, 25 
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10 µM; M8-B, 1 µM; TTX, 3 µM; A803467, 10 µM; ProTxII, 3 nM; GIIIA, 10 µM; TIIIA, 1 
10 µM) 5-15 min prior to behavioural quantification. To assess the effect of pharmacological 2 
modulators on the nocifensive responses elicited by 4-AP, compounds were co-administered 3 
by intraplantar injection as appropriately concentrated solutions (Cn2, l nM; GIIIA, 10 µM; 4 
TTX, 3 µM; AMTB, 10 µM; HC030031, 100 µM) in a final volume of 40 µl. 5 
No systemic effects, including ataxia, altered gait or motor paralysis were apparent in any 6 
mice or after intraplantar injection of any pharmacological modulators. In addition, no 7 
sustained hind paw favouring, inflammation, swelling or ulceration of the oxaliplatin-injected 8 
paw was visible. Injection of equal volumes of 5% glucose/H2O and phosphate-buffered 9 
saline with or without albumin did not elicit any nocifensive behaviour. 10 
 11 
FLIPR Membrane Potential Assays 12 
To verify the in vitro potency of compounds with activity Navl.6 channels, inhibition of 13 
veratridine-induced membrane potential responses were assessed using the FLIPR
TETRA 14 
(Molecular Devices, Sunnyvale, CA) plate reader. Nav1.6-expressing CHO cells (EZcells, 15 
Chantest, Cleveland, OH) were loaded with Red Membrane Potential dye (Molecular 16 
Devices), and responses to stimulation with veratridine (50 µM) were assessed after 5 min 17 
pre-treatment with antagonists as previously described [51]. 18 
 19 
Data and statistical analysis 20 
Fluorescence values from membrane potential imaging experiments were converted to 21 
response over baseline values using Screen Works 3.2.0.14 as previously described [51]. For 22 
concentration-response curves, maximum values from the response after addition of agonist 23 
were plotted against agonist concentration and a 4-parameter logistic Hill equation was fitted 24 
to the data using GraphPad Prism Version 5.03 (San Diego, CA). Statistical significance was 25 
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defined as p < 0.05 and was determined using paired or unpaired Student's t-tests and one-1 
way ANOVA analysis with Dunnett's post test as indicated. Statistical analysis was performed 2 
using GraphPad Prism Version 5.03.  3 
 4 
Results 5 
A mouse model of chemotherapy-induced cold allodynia based on intraplantar administration 6 
of oxaliplatin 7 
In humans, cold allodynia generally occurs during or within hours of oxaliplatin infusion and 8 
is characterized by pain in response to normally innocuous cooling, presumably resulting 9 
from a direct effect of oxaliplatin on peripheral sensory neurons. To isolate the actions of 10 
oxaliplatin on peripheral sensory neurons, we established a novel mouse model of oxaliplatin-11 
induced cold allodynia based on the administration of oxaliplatin by shallow subcutaneous 12 
(intraplantar, i.pl.) injection into the hind paw of C57/BL6J mice. Intraplantar injection of 13 
oxaliplatin (4–40 µg) elicited rapid, dose-dependent development of cold allodynia, 14 
evidenced by flinching, lifting, licking and shaking of the affected hind paw upon exposure to 15 
a cooled surface (10°C) (Fig. la).  16 
This dose (1.6-2.0 mg/kg) is approximately equivalent to human therapeutic doses (2.5-3.5 17 
mg/kg), and considerably lower than systemic doses previously reported to elicit acute cold 18 
allodynia in rodents (5 – 10 mg/kg) [60]. 19 
Strikingly, cold allodynia induced by a single dose of oxaliplatin became apparent within 20 
minutes of injection and persisted for several days, with significant pain behaviour evident for 21 
up to 7 days after injection of the highest dose (2.5 mM; 40 µg; Fig. lb). The terminal 22 
elimination phase of platinum-containing metabolites is long, suggesting that the prolonged 23 
effect of a single intraplantar injection of oxaliplatin could arise from the pharmacokinetics of 24 
these oxaliplatin metabolites. Alternatively, oxaliplatin, or platinum metabolites, may elicit 25 
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irreversible changes in neuronal proteins which are involved in mediating increased 1 
excitability to cool stimuli.  2 
Nocifensive behaviour evoked by intraplantar injection of oxaliplatin became apparent at 3 
temperatures below 15°C (18.2 ± 6.5 flinches/5 min), but no heat allodynia was evident, with 4 
animals displaying little or no nocifensive behaviour at elevated temperatures up to 42°C (1.0 5 
± 0.7 flinches/5 min) (Fig. 1c). In addition, intraplantar injection of oxaliplatin also elicited 6 
mechanical allodynia, evidenced by decreased paw withdrawal threshold to mechanical 7 
stimulation (Fig. 1d; Control, 4.7± 0.3 g; oxaliplatin 2.5 ± 0.3 g). Therefore, this novel animal 8 
model of intraplantar oxaliplatin produces behavioural responses that parallel the human 9 
symptomatology of oxaliplatin-induced neuropathy, confirming a direct peripheral effect of 10 
oxaliplatin on sensory nerve endings as the basis of cold-evoked paraesthesias and 11 
dysaesthesias. 12 
 13 
Oxaliplatin metabolites contribute to mechanical, but not cold allodynia 14 
Oxaliplatin is rapidly hydrolyzed in vivo to bioactive derivatives through displacement of the 15 
oxalate group by H2O and Cl
–
 to produce oxalate as well as reactive monochloro-, dichloro- 16 
and diaquo-diaminocyclohexane platinum metabolites [18; 22]. As these oxaliplatin 17 
metabolites have previously been suggested to contribute to oxaliplatin-induced neuropathy, 18 
we sought to characterize the contribution of oxalate and the oxaliplatin metabolite 19 
Pt(DACH)Cl2 to oxaliplatin-induced cold allodynia in our model. We found that intraplantar 20 
injection of equivalent doses of Pt(DACH)Cl2, (2.5 mM; 38 µg) or oxalate (2.5 mM; 14 µg) 21 
did not cause cold allodynia (Fig. 2a). However, injection of a higher dose of oxalate (150 22 
mM; 810 µg/paw) caused short-lived (< 1 h) spontaneous nocifensive behaviour, evidenced 23 
by lifting, licking and shaking of the paw (Fig. 2b), as well as mechanical allodynia which 24 
remained apparent 24 h after a single intraplantar injection of oxalate (Fig. 2c; Control, 4.4 ± 25 
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0.5 g; oxalate 0.9± 0.3 g). Consistent with the ability of oxalate to chelate Ca
2+
 [24], both the 1 
spontaneous pain (29.1 ± 5.1 flinches/5 min) and mechanical allodynia (2.6 ± 0.3 g) were 2 
mimicked by intraplantar injection of the Ca
2+
 chelator BAPTA (10 mM; 191 µg) (Fig. 2b 3 
and 2c). In contrast, intraplantar injection of the cell membrane-permeable BAPTA-AM [49] 4 
(10 µM; 310 ng) had no effect on spontaneous nocifensive behaviour and did not elicit cold 5 
allodynia (Fig. 2a-c). The effect of oxalate and BAPTA on sensory nerve endings likely arises 6 
from the destabilizing effect of Ca
2+
 chelation on neuronal membranes, with removal of 7 
extracellular Ca
2+
 leading to increased excitability by decreasing the threshold potential and 8 
membrane resistance, and increasing Na
+
 conductance  [20]. These effects have been shown 9 
in ex vivo preparations to result in spontaneous action potential discharge and an increase in 10 
mean firing frequency [25; 43],  corroborating the proalgesic effect of extracellular Ca
2+
 11 
chelation we observed in our animal model. 12 
 13 
Oxaliplatin-induced cold allodynia is mediated through Nav1.6-expressing peripheral sensory 14 
fibers 15 
Nav channels are critical for the propagation of action potentials in excitable cells, including 16 
peripheral sensory nerves. The tetrodotoxin-resistant isoform Nav1.8 in particular is crucial 17 
for neuronal excitability at cold temperatures and is essential for noxious cold pain [61]. Thus, 18 
we sought to elucidate the contribution of Navl.8 to oxaliplatin-induced cold allodynia. 19 
Surprisingly, the development of cold allodynia was unchanged in Nav1.8
–/–
 animals, and was 20 
also not affected by A803467, a Nav1.8-selective small molecule inhibitor (Fig. 3a; Nav1.8
–/–
, 21 
98 ± 15% of control; A803467 (10 µM), 90 ± 17% of control). Similarly, the tetrodotoxin-22 
resistant Navl.9 has previously been suggested to contribute to the pathogenesis of 23 
neuropathic pain and cold allodynia [29]. However, in our model the cold allodynia was 24 
unchanged in Nav1.9
–/–
 animals (Fig. 3a; 107 ± 8% of control), suggesting that TTX-sensitive 25 
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Nav isoforms are crucial for the development of oxaliplatin-induced cold allodynia. Indeed, 1 
intraplantar injection of low concentrations of TTX (3 µM) inhibited nocifensive responses 2 
upon exposure to a surface cooled to 10°C (Fig. 3a; 19 ± 4% of control). We thus assessed the 3 
contribution of Nav1.3 and Nav1.7 using knockout animals or subtype-selective inhibitors. 4 
Surprisingly, the development of cold allodynia was also unchanged in Nav1.3
–/–
 animals (103 5 
± 11% of control), or after intraplantar injection of the Navl.7-selective inhibitor ProTxII (3 6 
nM; 115 ± 17% of control) (Fig. 3b), suggesting involvement of Nav isoforms not typically 7 
attributed behavioural roles in pain pathways. In addition to Nav1.3, Nav1.7, Nav1.8 and 8 
Nav1.9, DRG neurons are known to express other tetrodotoxin-sensitive isoforms, including 9 
Nav1.1, Nav1.2 and Nav1.6. Since knockout mouse models of these Nav isoforms are lethal, 10 
we used a range of conotoxins with activity at Nav isoforms that allowed dissection of the 11 
contribution of these isoforms to oxaliplatin-induced pain pathways. µ-Conotoxin TIIIA 12 
specifically inhibits Navl.2 and Navl.4 at low concentrations, while at high concentrations 13 
Nav1.1, but not Nav1.6, is also inhibited [55; 59] (Fig. 3c; Nav1.6 pIC50 6.0 ± 0.3). Intraplantar 14 
injection of both low (100 nM) or high (10 µM) concentrations of TIIIA did not significantly 15 
decrease oxaliplatin-induced cold allodynia (Fig. 3 D), suggesting a crucial role for Navl.6 in 16 
cold pain pathways activated by oxaliplatin. Indeed, intraplantar injection of GIIIA (10 µM), 17 
which in addition to Nav1.1 also inhibits Nav1.6 at high concentrations, but has no effect on 18 
Nav1.3 and Nav1.7 [55], achieved near complete reversal of oxaliplatin-induced cold allodynia 19 
(14 ± 9% of control) (Fig. 3d). In contrast, nocifensive behavior elicited by intraplantar 20 
administration of the TRPA1 agonist AITC (allyl isothiocyanate, 5mM) was not affected by 21 
GIIIA (30 µM; Fig 3e). Thus, this demonstrates for the first time a functional contribution of 22 
Navl.6 to cold pain pathways at the behavioural level. 23 
 24 
Oxaliplatin-induced cold allodynia develops independently of cold-sensitive TRP channels 25 
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In peripheral sensory neurons, cold stimuli are transformed to electrical signals through 1 
activation of thermosensitive TRP channels, notably TRPM8, TRPA1 and TRPC5. We thus 2 
sought to elucidate the contribution of cold-sensitive TRP channels to the development of 3 
cold allodynia in our novel model of acute oxaliplatin-induced neuropathy. Surprisingly, 4 
oxaliplatin-induced cold allodynia was unaffected in TRPM8
–/–
 animals (128 ± 17% of 5 
control) or by the TRPM8-selective inhibitors AMTB (10 µM; 107 ± 13% of control) and 6 
M8-B (1 µM; 108 ± 13% of control) (Fig. 4). Cold allodynia was also not significantly 7 
decreased in TRPA1
–/–
 animals (115 ± 18% of control) or after treatment with the TRPA1 8 
antagonist HC030031 (100 µM; 76 ± 14% of control), and developed normally in TRPC5
–/–
 9 
animals (data not shown) (Fig. 4). Thus, alternative mechanisms to transform a cool stimulus 10 
to an electrical signal are likely to contribute to oxaliplatin-induced cold allodynia.  11 
 12 
It is known that cooling alters the membrane properties of excitable cells, leading to increased 13 
input resistance which in turn brings cells closer to the spiking threshold [23; 54]. In addition, 14 
in some sensory and central neurons, cooling elicits enhanced excitability and increased and 15 
increased firing frequency as a result of cold-induced closure of background potassium 16 
channels [3; 15; 34; 39; 53]. This effect appears to be opposed by continued activity of Kvl 17 
channels which act as an excitability break and regulate cold sensitivity in trigeminal neurons 18 
in concert with TRPM8 [33; 53]. 19 
Since it is known that oxaliplatin inhibits potassium channels [27] in addition to sodium 20 
channels [2; 8; 24; 28; 47], we assessed if the oxaliplatin-induced effects could be replicated 21 
by inhibition of delayed rectifier potassium channels in sensory nerve endings. Indeed, 22 
intraplantar injection of 4-AP (1 mM) elicited cold allodynia (35.2 ± 8.6 flinches/5 min) 23 
which was not affected by intraplantar injection of the TRPA1 inhibitor HC030031 (100 µM; 24 
37.4 ± 13.4 flinches/5 min) or the TRPM8 inhibitor AMTB (10 µM; 46.6 ± 10.5 flinches/5 25 
12 
 
min) (Fig. 5a). Like oxaliplatin-induced cold allodynia, enhanced nocifensive responses to 1 
cold elicited by 4-AP were inhibited by the Navl.6 inhibitor GIIIA (8.6 ± 4.4 flinches/5 min), 2 
confirming an important role for Navl.6 in cold pain pathways (Fig. 5 A).  3 
 4 
Pain behaviors induced by selective Nav1.6 activation 5 
To further characterize the role of Nav1.6 in pain pathways, we also assessed spontaneous 6 
pain behaviours, thermal allodynia and mechanical allodynia after intraplantar injection of the 7 
Nav1.6-selective activator Cn2. Cn2 is a β-scorpion toxin isolated from the venom of the 8 
scorpion Centruroides noxius that specifically enhances activity of Nav1.6 with an EC50 of 39 9 
nM, causing a leftward shift of the voltage-dependence of activation and a transient resurgent 10 
current [44]. Intraplantar injection of Cn2 elicited dose-dependent spontaneous pain 11 
characterized by licking, lifting and vigorous shaking of the injected paw that was transient 12 
for lower concentrations (1 nM, < 15 min). At the highest concentration tested (30 nM; Fig. 13 
5b), the frequency and severity of these responses rapidly diminished after injection, although 14 
some nocifensive behaviours remained evident for > 4 h after intraplantar administration. 15 
Thus, for subsequent experiments, low concentrations of Cn2 were utilized.   16 
Intraplantar Cn2 (1 nM) did not elicit thermal allodynia, with little or no nocifensive 17 
behaviour evident at 10°C or 42°C (Fig. 5c) but caused significant (p < 0.01) mechanical 18 
allodynia, evidenced by decreased paw withdrawal thresholds to mechanical stimulation (Fig. 19 
5d; Control, 5.4 ± 0.4 g; Cn2 (1 nM), 2.8 ± 0.6 g). To examine the contribution of potassium 20 
channels to Nav1.6-dependent cold-pain, we co-administered Cn2 (10 nM) with 4-AP (500 21 
µM) by intraplantar injection. As opposed to Cn2 alone, this combination potentiated the cold 22 
allodynia produced by 4-AP (Fig. 5e; 4-AP, 12.0 ± 3.1 flinches/5 min; 4-AP + Cn2, 38.0 ± 23 
8.2 flinches/5 min), providing evidence that activation of Nav1.6 per se produced only 24 
13 
 
spontaneous pain and mechanical allodynia, but when combined with inhibition of delayed 1 
rectifier potassium channels could enhance cold allodynia.  2 
 3 
Discussion 4 
Acute oxaliplatin-induced neuropathy occurs in almost all patients and manifests as 5 
circumoral and distal sensory and/or motor disturbances including paraesthesias and 6 
dysaesthesias and muscle fasciculations. These symptoms are triggered by exposure to  cold 7 
and are associated with a significant reduction in the cold pain threshold [6]. However, the 8 
pathophysiological basis of acute oxaliplatin-induced neuropathy, in particular cold allodynia, 9 
is poorly understood. This is in part due to a paucity of animal models that accurately reflect 10 
the neuropathic symptomatology encountered clinically and, specifically, the rapid onset of 11 
cold allodynia. To better understand chemically-induced cold allodynia, we established an 12 
animal model of chemotherapy-induced peripheral neuropathy based on the intraplantar 13 
injection of oxaliplatin. This model supports a direct excitatory action of oxaliplatin on 14 
peripheral sensory nerve endings as the causative mechanism underlying oxaliplatin-induced 15 
neuropathy, with cold allodynia becoming evident within minutes and persisting for several 16 
days after a single local injection of oxaliplatin. We were able to show that inhibition of 17 
potassium channels leads to increased neuronal excitability at low temperatures independent 18 
of activation of TRP channels, and that peripheral Navl.6 was crucial for the propagation of 19 
these signals and the appearance of cold allodynia.  20 
 21 
The metabolism of oxaliplatin is complex and involves rapid hydrolysis (t½α ~ 14 min) to 22 
oxalate and various bioactive platinum compounds, which in turn form adducts with DNA, 23 
proteins, peptides and amino acids that undergo slow, triphasic elimination through 24 
predominantly renal routes, with a long terminal half-life for platinum of up to 11 days [18; 25 
14 
 
22]. It is difficult to estimate the concentration of oxaliplatin that sensory neurons are exposed 1 
to in human patients. While the plasma concentration of free oxaliplatin after intravenous 2 
administration is relatively low [18; 22], consistent with an apparent large volume of 3 
distribution, oxaliplatin is likely to accumulate in sensory neurons through active transport by 4 
copper transporters and the L-carnitine transporter OCTN1 [26; 31].   5 
Given the rapid onset and prolonged nature of the sensory disturbances associated with 6 
oxaliplatin infusion [5], contribution of various oxaliplatin metabolites to the development of 7 
peripheral neuropathy has been suggested. In DRG explants, Pt(DACH)Cl2 was more 8 
neurotoxic than oxaliplatin [32], while after repeated intraperitoneal administration, oxalate 9 
elicited cold hyperalgesia and increased paw withdrawal responses to application of acetone, 10 
but not mechanical allodynia [42]. We thus assessed the effect of equimolar doses of oxalate 11 
and Pt(DACH)Cl2, two major oxaliplatin metabolites, on the development of cold and 12 
mechanical allodynia after intraplantar injection. However, while neither metabolite elicited 13 
cold allodynia after a single local injection, Ca
2+
 chelation by oxalate elicited spontaneous 14 
nocifensive behaviour as well as prolonged mechanical allodynia. This effect was mimicked 15 
by intraplantar injection of BAPTA and can be attributed to the effects of extracellular Ca
2+
 16 
removal on membrane properties, including decreased threshold potential and membrane 17 
resistance, as well as increased Na
+
 conductance [20].  18 
 19 
Acute oxaliplatin-induced neuropathy has been postulated to involve the modulation of 20 
axonal Nav channels, based on the observation that oxaliplatin infusion elicited changes in 21 
Nav-dependent variables in humans [28; 36]. Similarly, in rat DRG neurons, oxaliplatin 22 
resulted in increased Na
+
 currents and a shift of the voltage-response relationship towards 23 
more negative potentials, [2] with similar effects observed in cockroach neurons and frog 24 
myelinated axons [8; 24].  25 
15 
 
 1 
The lack of contribution of Navl.8 to oxaliplatin-induced cold allodynia, which we 2 
demonstrated in both Navl.8 knockout animals and after intraplantar administration of the 3 
Navl.8-selective inhibitor A803467, was surprising given the crucial role of this Nav isoform 4 
in cold pain. Specifically, Nav1.8 in nociceptive peripheral sensory neurons has previously 5 
been demonstrated to be critical for the development of pain evoked by noxious cold [61], and 6 
in mice with diphtheria toxin-mediated ablation of Nav1.8-expressing nociceptors, noxious 7 
cold responses are virtually abolished [1]. Oxaliplatin induces repetitive firing, broadening of 8 
the repolarization phase and after-hyperpolarization in myelinated A-fibers, while non-9 
myelinated C-fibers remain largely unaffected [2; 27; 46; 47]. In contrast, although Navl.8 is 10 
widely expressed in peripheral sensory neurons, including a subpopulation of myelinated A-11 
fibers [45], its contribution to cold-evoked pain behavior arises mainly from nociceptive C-12 
fibers [1; 52; 61]. Thus, our finding that Nav1.8 does not contribute to oxaliplatin-induced 13 
cold allodynia can be explained by the differential expression of Nav isoforms in peripheral 14 
sensory nerve fibers that contribute to the pathophysiology of oxaliplatin-induced cold 15 
allodynia. The role of Nav1.8 in pathological cold pain appears to be different from its role in 16 
physiological cold pain [61], and in addition differs to other models of chemically-induced 17 
cold allodynia, such as ciguatoxin-induced cold pain, where Nav1.8 still contributes 18 
significantly to pain behaviours [52].   19 
 20 
Consistent with a major role for Navl.6 in the propagation of action potentials in myelinated 21 
A-fibers [55; 59], we found no contribution of Navl.3, Nav1.7 and Nav1.9 to oxaliplatin-22 
induced cold allodynia, while pharmacological inhibition of Navl.6 virtually abolished pain 23 
behaviour. Supporting a crucial role for Navl.6 in oxaliplatin-induced cold allodynia is the 24 
observation that in vitro, oxaliplatin elicits Navl.6-mediated resurgent currents and that 25 
16 
 
oxaliplatin-induced A-fiber effects were abolished in Navl.6 knockout animals [47]. Similarly, 1 
we observed significant potentiation of veratridine-induced Nav1.6 responses in our 2 
membrane potential assay (data not shown), consistent with the previously reported effect of 3 
oxaliplatin on fast inactivation [47]. 4 
 5 
Thus, we have obtained the first evidence that Navl.6 expressed in peripheral sensory neurons 6 
contributes to cold pain behaviours. However, since Nav1.6 is highly expressed at nodes of 7 
Ranvier in both peripheral sensory and motor axons, as well as nodes in the central nervous 8 
system [10], Nav1.6 would be difficult to target therapeutically. Indeed, mice with loss-of-9 
function mutations in Scn8a, the gene encoding for Navl.6, are characterized by early onset 10 
progressive paralysis of the hind limbs, leading to juvenile lethality at approximately 11 
postnatal day 20 [9]. Thus, the results presented here support a role for Nav1.6 in pathological 12 
pain states. Future experiments in sensory fiber-specific knockout model would be valuable to 13 
further dissect the role of Navl.6 in pain pathways.  14 
 15 
Thermosensitive TRP channels, in particular TRPM8, TRPA1 and TRPC5, are expressed in 16 
peripheral sensory neurons and are activated by cooling [37; 48; 62]. Chronic administration 17 
of oxaliplatin in animal models has been shown to elicit changes in TRP channel expression, 18 
and both TRPM8 and TRPA1 have been causally implied in the development of 19 
chemotherapy-induced cold allodynia [21; 35; 60].  However, the rapid onset of cold 20 
allodynia both clinically and in our novel model of acute oxaliplatin-induced cold allodynia 21 
suggests that changes in the expression level of TRP channels are unlikely to contribute to the 22 
observed symptomatology. Indeed, we found no significant effect of TRPA1, TRPM8 or 23 
TRPC5 to oxaliplatin-induced cold allodynia using both genetically modified animals and 24 
pharmacological modulators where possible. This finding is consistent with the 25 
17 
 
predominantly A-fiber-mediated origin of oxaliplatin-induced cold allodynia, as cold-1 
sensitive TRP channels are expressed predominantly on peptidergic and isolectin B4-positive 2 
C-fibers [17; 48; 62].  3 
Activation of TRPM8 by cooling has been demonstrated in peripheral sensory neurons, 4 
trigeminal neurons and corneal neurons [7; 11; 17] .  In addition, heterologously expressed 5 
TRPM8 is also activated by cooling, and a role for TRPM8 has been demonstrated in 6 
environmental cold sensing as well as noxious cold pain in several behavioural studies [7; 13]. 7 
We found a significant response to acetone in naïve C57BL/6 mice, consisting of vigorous 8 
shaking, licking and aversive behaviours, and for this reason chose to assess cold pain 9 
behaviour by exposure to a temperature-controlled plate.  Previous studies have also reported 10 
sensitivity to acetone in naïve animals, which was decreased in TRPM8 knockout animals 11 
[13]. This observation could account for the effect of TRPM8 on oxaliplatin-induced cold 12 
allodynia previously reported. 13 
 14 
An alternative mechanism of inducing cold sensitivity is based on inhibition of potassium 15 
channels. In addition to modulation of Nav, oxaliplatin also inhibits neuronal potassium 16 
channels [8; 27]. In peripheral myelinated fibers, the effects of oxaliplatin on compound 17 
action potentials were similar to those of 4-AP [27]. 4-AP inhibits delayed-rectifier channels, 18 
including Kv1.1 and Kv1.2 which have been shown to be highly expressed in cold-insensitive 19 
neurons and contribute to lack of cold-sensitivity in trigeminal neurons [33; 50; 53].  Indeed, 20 
intraplantar injection of 4-AP caused behavioural responses similar to oxaliplatin, and elicited 21 
cold allodynia that was not modulated by inhibition of TRPM8 or TRPA1, but was decreased 22 
by pharmacological inhibition of Nav1.6. These findings are consistent with Kv1.1 and Kv1.2 23 
being expressed predominantly in large DRG neurons which give rise to myelinated A-fibers 24 
[38], and corroborate an important role for Kv channels in cold sensing and cold allodynia. 25 
18 
 
Indeed, activation of Nav1.6 alone was not sufficient to elicit cold allodynia, with the Nav1.6-1 
specific scorpion toxin Cn2 eliciting spontaneous pain and mechanical allodynia but not cold 2 
allodynia. However, when combined with inhibition of Kv channels, Cn2 produced profound 3 
enhancement of 4-AP-induced cold allodynia. Thus Cn2 not only confirms the pivotal role 4 
played by Nav1.6 in chemically-induced cold pain but reveals a role for Nav1.6 in spontaneous 5 
pain and mechanical allodynia. In conclusion, the new animal model of oxaliplatin-induced 6 
cold allodynia described here reveals an important role for Nav1.6 in pain pathways, with 7 
chemically-induced cold allodynia mediated through inhibition of potassium channels on 8 
Navl.6-expressing peripheral sensory fibers. 9 
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Figure captions 1 
2 
Figure 1. A novel animal model of chemotherapy-induced neuropathy based on the 3 
intraplantar injection of oxaliplatin. (a) Intraplantar injection of oxaliplatin (4 – 40 µg/paw) 4 
rapidly elicits cold allodynia, with increased paw lifting, licking, shaking and flinching 5 
evident 1 h after injection upon exposure to a temperature-controlled surface maintained at 6 
10°C. Injection of vehicle (Control; 5% glucose/H2O) did not elicit any nocifensive responses. 7 
(b) Oxaliplatin-induced cold allodynia has a rapid onset (left panel, 0-4 h post-injection), with 8 
nocifensive responses upon exposure of the injected hind paw to cool temperatures becoming 9 
apparent within minutes after injection (arrow). Cold allodynia after a single injection persists 10 
for several days (right panel, 4 h - 9 days post-injection) after intraplantar injection (arrow). 11 
(c) Nocifensive responses evoked by intraplantar injection of oxaliplatin (40 µg/paw) are 12 
temperature-dependent, with significant paw withdrawals elicited upon exposure to 13 
temperatures below 15°C (24 h after injection). No withdrawal responses were evident at 14 
28 
 
elevated temperatures up to 42°C. White bar; for all subsequent experiments, cold allodynia 1 
was assessed 24 h after injection of 40 µg oxaliplatin/paw by quantifying paw withdrawal 2 
responses at 10°C. (d) Intraplantar injection of oxaliplatin (40 µg/paw) elicited mild 3 
mechanical allodynia, with a significant decrease in paw withdrawal threshold to mechanical 4 
stimulation compared to control (5% glucose/H2O). Left panel, decreased mechanical 5 
threshold was apparent at 1 h after injection and persisted 24 h after injection (right panel). 6 
Statistical significance was determined using an unpaired Student's t-test; ***, p < 0.001; **, 7 
p < 0.01 compared to vehicle. Data are presented as mean ± SEM (n = 5- 12 animals/group). 8 
 9 
10 
Figure 2. Oxaliplatin metabolites contribute to mechanical, but not cold allodynia. (a) 11 
Intraplantar injection of equimolar doses of the oxaliplatin metabolites Pt(DACH)Cl2  (2.5 12 
mM; 38 µg/paw) and oxalate (2.5 mM; 14 µg/paw) did not elicit paw withdrawal responses at 13 
10°C, compared to the pronounced cold allodynia elicited by oxaliplatin (2.5 mM; 40 14 
µg/paw). Cold allodynia was also not elicited by intraplantar injection of the Ca
2+
 chelator 15 
BAPTA (10 mM; 191 µg/paw) or the membrane-permeable BAPTA-AM (10 µM; 310 16 
ng/paw). (b) Intraplantar injection of high doses of oxalate (150 mM; 810 µg/paw) and 17 
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BAPTA (10 mM; 191 µg/paw), but not low doses of oxalate, oxaliplatin, BAPTA-AM or  1 
Pt(DACH)Cl2, elicited short-lasting (< 1 h) spontaneous nocifensive behaviour (increased 2 
number of paw lifts, licks, shakes and flinches) evident at room temperature. (c) Intraplantar 3 
injection of high doses of oxalate (150 mM; 810 µg/paw), BAPTA (10 mM; 191 µg/paw) and 4 
oxaliplatin (2.5 mM; 40 µg/paw) caused a significant decrease in the paw withdrawal 5 
threshold to mechanical stimulation, while mechanical responses were unchanged after 6 
intraplantar injection of equimolar doses of Pt(DACH)Cl2, and oxalate. Statistical 7 
significance was determined using a one-way ANOVA with Dunnett’s post test. ***, p < 8 
0.001; **, p < 0.01 compared to Control (vehicle). Data are presented as mean ± SEM (n = 3 9 
– 5) animals/group. 10 
 11 
12 
Figure 3. Nav isoforms involved in the development of cold allodynia after intraplantar 13 
injection of oxaliplatin. (a) Cold allodynia induced by intraplantar injection of oxaliplatin 14 
(24 h after injection of 2.5 mM oxaliplatin; 40 µg/paw) was not significantly different from 15 
control in Navl.8
–/–
 animals, or after intraplantar injection of the Navl.8 inhibitor A803467 (10 16 
µM). Paw flinches were also not significantly different from control in Navl.9
–/–
 animals, but 17 
were significantly (p < 0.01) inhibited by intraplantar injection of TTX (3 µM). (b) 18 
Oxaliplatin-induced cold allodynia was not significantly different from control in Navl.3
–/–
 19 
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animals, or after intraplantar injection of the Navl.7 inhibitor ProTxII (3 nM). (c) µ-Conotoxin 1 
GIIIA concentration-dependently (pIC50 6.0 ± 0.3) inhibits Navl.6, while TIIIA does not affect 2 
Navl.6-mediated responses. Effect of µ-conotoxins on veratridine (50 µM)-induced Navl.6 3 
responses was assessed using a FLIPR membrane-potential assay in HEK cells heterologously 4 
expressing Navl.6. (d) Intraplantar injection of TIIIA at concentrations which inhibit Navl.2 5 
(100 nM), or Navl.1 but not Navl.6 (10 µM) did not significantly decrease oxaliplatin-induced 6 
cold allodynia. In contrast, GIIIA at a concentration which fully inhibits Navl.6 (10 µM) 7 
caused near complete inhibition of cold allodynia. (e) GIIIA (30 µM) had no effect on 8 
nocifensive behaviours elicited by intraplantar administration of the TRPA1 agonist AITC (5 9 
mM). Data is presented relative to vehicle-injected wi1d-type animals or age-matched litter 10 
controls. Statistical significance was determined using a one-way ANOVA with Dunnett's 11 
post test. **, p < 0.01 compared to Control (vehicle or age-matched litter controls). Data are 12 
presented as mean± SEM (n = 4 – 8 animals/group). 13 
 14 
Figure 4. Oxaliplatin-induced cold allodynia 15 
develops independently of cold-sensitive TRP channels. Oxaliplatin-induced cold allodynia 16 
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was not changed in TRPM8
–/–
 animals or after intraplantar injection of the TRPM8 1 
antagonists AMTB (10 µM) and M8-B (1 µM). Similarly, no significant difference in the 2 
number of paw flinches was observed in TRPA1
–/–
 animals or after intraplantar injection of 3 
the TRPA1 antagonist HC030031 (100 µM). Statistical significance was determined using a 4 
one-way ANOVA with Dunnett's post test. Data are presented as mean ± SEM (n = 5–10 5 
animals/group). 6 
 7 
 8 
9 
Figure 5. Inhibition of potassium channels on Nav1.6-expressing pain pathways elicits 10 
cold allodynia. (a) Intraplantar injection of the potassium channel inhibitor 4-AP (1 mM) 11 
elicited cold allodynia, evidenced by an increased number of paw lifts, licks, shakes and 12 
flinches on exposure to a temperature-controlled plate maintained at 10°C. Cold allodynia 13 
induced by 4-AP was not significantly inhibited by concomitant intraplantar injection of the 14 
TRPM8 antagonist AMTB (10 µM) or the TRPA1 antagonist HC030031 (100 µM), but was 15 
significantly (p < 0.05) inhibited by intraplantar µ-conotoxin GIIIA (10 µM).  (b) Intraplantar 16 
injection of Cn2 (1 nM – 30 nM) elicited dose-dependent spontaneous pain. Responses were 17 
quantified by counting the number of behaviours immediately after injection (c) Activation of 18 
peripheral Nav1.6 by Cn2 (1 nM) did not elicit cold (10°C) or heat (42°C) allodynia. (d) 19 
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Intraplantar Cn2 (1 nM) caused significant (p < 0.01) mechanical allodynia, with the paw 1 
withdrawal threshold to mechanical stimulation decreased from 5.4 ± 0.4 g (control) to 2.8 ± 2 
0.6 g (Cn2, 1 nM). (e) Intraplantar injection of the Nav1.6 activator Cn2 (10 nM) alone did not 3 
elicit significant cold allodynia (1.7 ± 1.5 flinches/5 min at 10°C), but significantly (p < 0.05) 4 
potentiated cold allodynia elicited by intraplantar injection of 4-AP (500 µM; 12.0 ± 3.1 5 
flinches/5 min at 10°C) when co-administered (4-AP + Cn2; 38.0 ± 8.2 flinches/5 min). 6 
Statistical significance was determined using a one-way ANOVA with Dunnett's post test. *, 7 
p < 0.05; **, p < 0.01 compared to control. Data are presented as mean ± SEM (n = 4 – 7 8 
animals/group). 9 
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